![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 33, 23341-23348, August 13, 1999
and BLTR, Nuclear and Cell
Surface Receptors for Leukotriene B4
,
,
,
, and
From the Peroxisome proliferator-activated receptor
Institut de Biologie Animale, Bâtiment
de Biologie, Université de Lausanne,
CH-1015 Lausanne, Switzerland, the
Dana Farber Cancer
Institute, Harvard Medical School, Boston, Massachusetts 02115, and
¶ Schering AG, Institute for Cell and Molecular Biology,
Berlin D-1000, Germany
(PPAR
)is a nuclear receptor for various fatty acids,
eicosanoids, and hypolipidemic drugs. In the presence of ligand, this
transcription factor increases expression of target genes that are
primarily associated with lipid homeostasis. We have previously
reported PPAR
as a nuclear receptor of the inflammatory mediator
leukotriene B4 (LTB4) and demonstrated an
anti-inflammatory function for PPAR
in vivo (Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez,
F. J., and Wahli, W. (1996) Nature 384, 39-43).
LTB4 also has a cell surface receptor (BLTR) that mediates
proinflammatory events, such as chemotaxis and chemokinesis (Yokomizo,
T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997)
Nature 387, 620-624). In this study, we report on chemical
probes that differentially modulate activity of these two
LTB4 receptors. The compounds selected were originally
characterized as synthetic BLTR effectors, both agonists and
antagonists. Here, we evaluate the compounds as effectors of the three
PPAR isotypes (
,
, and
) by transient transfection assays and
also determine whether the compounds are ligands for these nuclear
receptors by coactivator-dependent receptor ligand interaction assay, a
semifunctional in vitro assay. Because the compounds are
PPAR
selective, we further analyze their potency in a biological
assay for the PPAR
-mediated activity of lipid accumulation. These
chemical probes will prove invaluable in dissecting processes that
involve nuclear and cell surface LTB4 receptors and also
aid in drug discovery programs.
This article has been cited by other articles:
![]() |
P. R. Devchand, O. Ziouzenkova, and J. Plutzky Oxidative Stress and Peroxisome Proliferator-Activated Receptors: Reversing the Curse? Circ. Res., December 10, 2004; 95(12): 1137 - 1139. [Full Text] [PDF] |
||||
![]() |
A. J. Schottelius, C. Giesen, K. Asadullah, I. M. Fierro, S. P. Colgan, J. Bauman, W. Guilford, H. D. Perez, and J. F. Parkinson An Aspirin-Triggered Lipoxin A4 Stable Analog Displays a Unique Topical Anti-Inflammatory Profile J. Immunol., December 15, 2002; 169(12): 7063 - 7070. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kilfeather 5-Lipoxygenase Inhibitors for the Treatment of COPD* Chest, May 1, 2002; 121(5_suppl): 197S - 200S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Woo, H.-J. You, S.-H. Cho, Y.-W. Eom, J.-S. Chun, Y.-J. Yoo, and J.-H. Kim Leukotriene B4 Stimulates Rac-ERK Cascade to Generate Reactive Oxygen Species That Mediates Chemotaxis J. Biol. Chem., March 1, 2002; 277(10): 8572 - 8578. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Goulet, R. C. Griffiths, P. Ruiz, R. B. Mannon, P. Flannery, J. L. Platt, B. H. Koller, and T. M. Coffman Deficiency of 5-Lipoxygenase Accelerates Renal Allograft Rejection in Mice J. Immunol., December 1, 2001; 167(11): 6631 - 6636. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yokomizo, K. Kato, K. Terawaki, T. Izumi, and T. Shimizu A Second Leukotriene B4 Receptor, BLT2: A New Therapeutic Target in Inflammation and Immunological Disorders J. Exp. Med., August 8, 2000; 192(3): 421 - 432. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |